The Medical Insurance Bureau supports "same disease, same quality, same price"!

At 3 pm on June 7, the State Council Information Office held a regular State Council policy briefing on the newly issued "Opinions on Promoting the High-quality Development of Public Hospitals"
.

Li Bin, deputy director of the National Health Commission, and relevant persons in charge of the National Development and Reform Commission and the National Medical Insurance Administration introduced their opinions on promoting the high-quality development of public hospitals and answered reporters’ questions

At 3 pm on June 7, the State Council Information Office held a regular State Council policy briefing on the newly issued "Opinions on Promoting the High-quality Development of Public Hospitals"

The meeting emphasized that to promote the high-quality development of public hospitals, we must first build a new system, build national medical centers and regional medical centers, build provincial-level high-level hospitals, and reduce cross-provincial medical care

How will the Chinese patent medicine market change?

At the meeting, the issue of payment method reform was the topic that received the most media attention
.

It is reported that all the 30 pilot cities of DRG payment have entered the simulation operation, and some cities have already started the payment work

In addition, the Medical Insurance Bureau has also explored medical insurance payment methods that conform to the characteristics of traditional Chinese medicine, promoted the payment of superior diseases of traditional Chinese medicine according to the disease, and encouraged traditional Chinese medicine and the corresponding western medicine to achieve "same disease, same quality, same price"
.

It is understood that since June 2018, the Guangxi Liuzhou Medical Insurance Bureau has combined the DRG payment standard to apply the reform concept of Chinese and Western medicine in the same city, same disease, same effect, same price
.

In order to prevent possible low-indication admissions and decline in the quality of medical services after the implementation of traditional Chinese medical efficiency value payment, experts from Liuzhou Medical Insurance Bureau formulated the clinical path of each disease value payment disease to determine the corresponding admission standards.

From the perspective of local practice, the diagnosis and treatment of traditional Chinese medicine will be more standardized in the future, and it will show better clinical advantages in indication research
.

According to data from Mi Nei.

After the addition of drugs and consumables is cancelled, the "budget + cost" management of public hospitals becomes more important, and the reform of payment methods directly affects prescription behavior
.

Promote the construction of regional medical centers

New opportunities in the county market?

To build a new system for the high-quality development of public hospitals, it is necessary to give play to the leading and leading role of public hospitals in urban medical groups and county medical communities
.

The current pilot work for promoting the construction of regional medical centers: Hebei, Liaoning, Shanxi, Fujian, Anhui, Yunnan and other eight provinces have been selected to carry out pilot work, and the 10 projects that have been promoted have been completed and put into use successively

From the monitoring data, these projects have played a significant role in retaining local and even surrounding patients
.

There is a regional medical center in Henan, the Zhengzhou Hospital of Beijing Children's Hospital.

According to this trend, it is speculated that regional medical care will drastically change the flow of patients to seek medical care
.

In other words, the drug market will also sink to the grassroots level

Experts believe that it is mainly directly related to the lack of primary diagnosis and treatment capabilities
.
In the first half of 2020, AstraZeneca’s China market revenue reached US$2.
659 billion, an increase of 14% against the trend, mainly due to the performance of the county market offsetting the decline in the performance of the big cities; Novartis Pharma’s performance in hypertension, blood sugar, blood lipids, heart disease A wide range of disease fields such as aging, ophthalmology, and immunodermatology sink to the grassroots; BeiGene has also established a full-time county-level oncology team, which is responsible for tislelizumab, zebutinib, desulzumab, lenalidomide, etc.
Heavy new products
.
For another example, most of the drug sales of Huanzhen Pharmaceutical come from rural and urban grassroots markets; a lot of Yangzijiang's drug sales also come from rural and urban areas
.
It can be seen that medicine must go to the grassroots level, and department construction and doctor-patient education must go to the grassroots level
.